Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 8/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | ACACB | O00763 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | PHGDH | O43175 | 1/20 | 0.45 |
| ▸ | GRM5 | P41594 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | GPR183 | P32249 | 1/20 | 0.44 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5050543 | 0.95 | HPGD (0.50) | HPGDSMN1; SMN2ACACBALDH1A1PHGDH | |
| SCHEMBL5568925 | 0.84 | ACACB (0.44) | HPGDSMN1; SMN2ACACBALDH1A1TSHR | |
| SCHEMBL5567080 | 0.82 | HPGD (0.55) | HPGDSMN1; SMN2ALDH1A1PHGDHTSHR | |
| SCHEMBL5567078 | 0.81 | HPGD (0.54) | HPGDSMN1; SMN2ALDH1A1PHGDHTSHR | |
| SCHEMBL5046684 | 0.80 | ACACB (0.61) | ACACBALDH1A1TSHRKDM4EMAPT | |
| SCHEMBL5046909 | 0.77 | ACACB (0.55) | HPGDSMN1; SMN2ACACBALDH1A1TSHR | |
| SCHEMBL3638832 | 0.75 | GRM5 (0.60) | HPGDSMN1; SMN2ACACBALDH1A1PHGDH | |
| SCHEMBL3644126 | 0.75 | GRM5 (0.71) | HPGDSMN1; SMN2ACACBALDH1A1PHGDH | |
| SCHEMBL5046845 | 0.75 | ACACB (0.56) | ACACBGRM5MAPT | |
| SCHEMBL5046536 | 0.74 | ACACB (0.54) | HPGDSMN1; SMN2ACACBALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7459480-B2 | Benzodioxepine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-12-02 | — | — | US | disclosed |
| EP-1682528-B1 | BENZO [b][1,4] DIOXEPINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2007-09-12 | — | — | EP | disclosed |
| EP-1682528-A1 | BENZO [b][1,4] DIOXEPINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-07-26 | — | — | EP | disclosed |
| US-20050113374-A1 | Benzodioxepine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2005-05-26 | — | — | US | disclosed |
| WO-2005044814-A1 | BENZO [b][1,4] DIOXEPINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113374-A1 | Benzodioxepine derivatives | BBOX1, ACOX1, ACOX3 | HPGD 260/4885SMN1; SMN2 3955/4885ACACB 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.